Home Cart Sign in  
Chemical Structure| 6385-02-0 Chemical Structure| 6385-02-0

Structure of Meclofenamic acid sodium
CAS No.: 6385-02-0

Chemical Structure| 6385-02-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Meclofenamate Sodium is a dual COX-1/COX-2 inhibitor with IC50 of 40 nM and 50 nM, respectively, used in the treatment of joint, muscular pain, arthritis and dysmenorrhea.

Synonyms: Meclofenamate sodium; Meclofenamate (sodium salt); Meclofenamic Acid

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Meclofenamic acid sodium

CAS No. :6385-02-0
Formula : C14H10Cl2NNaO2
M.W : 318.13
SMILES Code : O=C([O-])C1=CC=CC=C1NC2=C(Cl)C=CC(C)=C2Cl.[Na+]
Synonyms :
Meclofenamate sodium; Meclofenamate (sodium salt); Meclofenamic Acid
MDL No. :MFCD00077376
InChI Key :OGPIIGMUPMPMNT-UHFFFAOYSA-M
Pubchem ID :4038

Safety of Meclofenamic acid sodium

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • COX-2

    COX-2, IC50:50 nM

  • COX-1

    COX-1, IC50:40 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
N87 0 μM, 10 μM, 20 μM, 30 μM, 40 μM, 50 μM To evaluate the effect of Meclofenamic acid on the proliferation of N87 cells, results showed that Meclofenamic acid inhibited N87 cell growth in a dose-dependent manner. PMC11705778
HGC27 0 μM, 10 μM, 20 μM, 30 μM, 40 μM, 50 μM To evaluate the effect of Meclofenamic acid on the proliferation of HGC27 cells, results showed that Meclofenamic acid inhibited HGC27 cell growth in a dose-dependent manner. PMC11705778
HeLa cells 80 μM and 120 μM 24 h To investigate the effect of MA2 on the level of m6A modification in HeLa cells, the results showed that MA2 significantly increased the level of m6A modification. PMC4288171
Mouse aortic smooth muscle cells 20 µM Meclofenamic acid (20 µM) relaxed aortic segments precontracted with phenylephrine, and this relaxation was reversed by the Kv7 channel blocker XE991. PMC2014117
GC-1 spg cells 40, 80, 120 μM 48 h MA2 significantly increased the cellular m6A level and down-regulated the expression of CDK1, CDK2, CDK6 and CdC25a, resulting in arrest of G1/S transition and decrease of cell proliferation. PMC6621992
Bladder smooth muscle cells (SMC) 1 µM MFA significantly reduced contraction amplitude, AUC, and baseline tone in bladder strips PMC3746117
HPC cells 50 mM Treatment with MA2 significantly upregulated RNF183 protein levels, indicating that MA2 reversed the high glucose-induced downregulation of RNF183 expression by inhibiting m6A demethylase activity. PMC11899265

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Hemorrhage-induced thalamic pain model Intraperitoneal injection 1, 5, 10 mg/kg Once daily for five days MA significantly attenuated the Coll IV microinjection-induced TLR4 upregulation and contralateral mechanical allodynia, heat hyperalgesia, and cold hyperalgesia. PMC8423095
Fetal lambs Fetal lambs Intravenous or intracerebral 0.8-10 mg/kg or 0.6-2.6 mg/kg Not specified Meclofenamate induced prolonged fetal breathing with a significant increase in breath amplitude, without altering blood gas values, heart rate, blood pressure, electrocortical activity, or eye movements. PMC1192907

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02429570 Recurrent Brain Metastases ... More >> Progressive Brain Metastases Less << Not Applicable Active, not recruiting April 2019 United States, Florida ... More >> Baptist Health South Florida Miami, Florida, United States, 33143 United States, New Jersey Memoral Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States, 07748 United States, New York Memorial Sloan Kettering Cancer Center at Commack Commack, New York, United States, 11725 Memorial Sloan Kettering Westchester Harrison, New York, United States, 10604 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, Pennsylvania Lehigh Valley Health Network Allentown, Pennsylvania, United States, 18103 Less <<
NCT02930005 Psychotic Disorders ... More >> Schizophrenia Schizoaffective Disorder Bipolar Disorder Less << Phase 2 Enrolling by invitation November 4, 2017 United States, Texas ... More >> Harris County Psychiatric Center Houston, Texas, United States, 77021 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.14mL

0.63mL

0.31mL

15.72mL

3.14mL

1.57mL

31.43mL

6.29mL

3.14mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories